-
公开(公告)号：US10851354B2
公开(公告)日：2020-12-01
申请号：US16198401
申请日：2018-11-21
摘要： The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1α in neurons. The invention also provides HSV vectors for expressing PP1α within neurons and compositions comprising such vectors.
-
2.发明申请公开(公告)号：US20200148742A1
公开(公告)日：2020-05-14
申请号：US16309862
申请日：2017-06-14
摘要： Provided is a recombinant viral vector that expresses a NKG2D activating ligand, such as a UL-16 binding protein. When introduced into a cancer cell, the vector can cause expression of the NKG2D activating ligand, thereby overcoming repression of NK-mediated (or other effector cell, e.g., macrophage) cytotoxicity and causing effector cell-mediated death of the cancer cell. Expression of the NKG2D activating ligand can be controlled by a miRNA present in greater concentration in noncancerous cells than in cancer cells, which can permit selective expression of the ligand in cancer cells and reduced cytotoxicity toward noncancerous cells. The vector can cause expression of an oncolytic factor. When formulated into a pharmaceutical composition and administered to a patient, the vector can be used to treat cancer. The cancer can be a glioma, such as glioblastoma including one with an isocitrate dehydrogenase (IDH) mutation. The vector can be a herpes simplex virus vector, among others.
-
公开(公告)号：US10201575B2
公开(公告)日：2019-02-12
申请号：US15032958
申请日：2014-10-28
IPC分类号： C12N15/00 , A61K48/00 , A61K35/763 , C12N7/00 , C07K14/005
摘要： The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and a plurality of copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells, and a deletion of the internal repeat (joint) region in the HSV genome comprising one copy of the ICP0, ICP34.5, LAT, and ICP4 genes and the ICP47 promoter. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
-
公开(公告)号：US10172893B2
公开(公告)日：2019-01-08
申请号：US15616585
申请日：2017-06-07
IPC分类号： C12N15/00 , A61K35/763 , C12N7/00 , C07K14/005
摘要： The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.
-
公开(公告)号：US20170189514A1
公开(公告)日：2017-07-06
申请号：US15409245
申请日：2017-01-18
CPC分类号： A61K39/0011 , A61K2039/585 , C07K14/005 , C12N7/00 , C12N15/86 , C12N15/8695 , C12N2710/16621 , C12N2710/16622 , C12N2710/16643 , C12N2710/16671 , C12N2810/6009 , C12N2810/851 , C12N2810/859
摘要： In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.
-
公开(公告)号：US11419926B2
公开(公告)日：2022-08-23
申请号：US16417254
申请日：2019-05-20
IPC分类号： A61K35/763 , C12N15/869 , C12N15/38 , A61K48/00 , A61K35/00 , A61K39/00 , C07K14/005 , C12N7/00 , C12N15/86
摘要： In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.
-
公开(公告)号：US20210121513A1
公开(公告)日：2021-04-29
申请号：US17058379
申请日：2019-05-31
申请人： University of Pittsburgh - Of the commonwealth System of Higher Education , Trustees of the University of Pennsylvania
发明人： Joseph C. Glorioso, III , Gary H. Cohen , Doina Atanasiu , Tina Marie Cairns , Bonnie Lynn Hall , Justus B. Cohen , Ceren Tuzmen
IPC分类号： A61K35/763 , C12N7/00
摘要： Provided herein are antigenically stealthed HSV particles, and methods of use of the antigenically-stealthed HSV particles.
-
公开(公告)号：US20200147189A1
公开(公告)日：2020-05-14
申请号：US16417254
申请日：2019-05-20
IPC分类号： A61K39/00 , C12N15/869 , C12N15/86 , C12N7/00 , C07K14/005
摘要： In one embodiment, the invention provides an HSV vector comprising a mutant gB and/or a mutant gH glycoprotein, where the viral envelope further comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type. In another embodiment, the invention provides an HSV vector comprising (a) a mutant gC and/or gD envelope glycoprotein which comprises a non-native ligand specific for a protein present on the surface of a predetermined cell type; and (b) a mutant envelope glycoprotein other than gD.
-
公开(公告)号：US10576115B2
公开(公告)日：2020-03-03
申请号：US16191141
申请日：2018-11-14
IPC分类号： C12N15/00 , A61K35/763 , C12N7/00 , C07K14/005
摘要： The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.
-
公开(公告)号：US20190262410A1
公开(公告)日：2019-08-29
申请号：US16191141
申请日：2018-11-14
IPC分类号： A61K35/763 , C07K14/005 , C12N7/00
摘要： The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.031 秒)
